title: Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.
authors.affiliation: Department of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, University Hospital of Tuebingen, Tuebingen, Germany.
authors.forename: Manola
authors.initials: M
authors.lastname: Zago
authors.affiliation: Department of General Pathology, University Hospital of Tuebingen, Tuebingen, Germany.
authors.forename: Patrick
authors.initials: P
authors.lastname: Adam
authors.affiliation: Department of Internal Medicine V and National Center for Tumor Diseases, University Hospital of Heidelberg, Heidelberg, Germany.
authors.forename: Hartmut
authors.initials: H
authors.lastname: Goldschmidt
authors.affiliation: Department of General Pathology, University Hospital of Tuebingen, Tuebingen, Germany.
authors.forename: Falko
authors.initials: F
authors.lastname: Fend
authors.affiliation: Department of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, University Hospital of Tuebingen, Tuebingen, Germany.
authors.forename: Lothar
authors.initials: L
authors.lastname: Kanz
authors.affiliation: Department of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, University Hospital of Tuebingen, Tuebingen, Germany. Electronic address: katja.weisel@med.uni-tuebingen.de.
authors.forename: Katja
authors.initials: K
authors.lastname: Weisel
mesh_terms: D001402:B-Lymphocytes / Q000187:drug effects* / Q000473:pathology; D005260:Female; D006689:Hodgkin Disease / Q000209:etiology* / Q000473:pathology; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use*; D000077269:Lenalidomide; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide
keywords: B-cell clonality; EBV; High-dose mephalan; Secondary primary malignancy; Thalidomide